venetoclax,acalabrutinib,obinutuzumab
roche,astrazeneca,abbvie
['equate', 'leusm', 'cll', 'obinu', 'venetoclax', 'acalabrutinib', '2018', 'lymsm']
great presentation by on combination acalabrutinib, venetoclax &amp; obinutuzumab (avo) in newly-diagnosed cll, with time-limited therapy for pts achieving mrd negativity #lymsm #leusm #ash22 
haematology registrar | fellow @PORTAL_research @harvardmed |
evidence-based medicine | health policy | lymphoma | myeloma |
Fulbright scholar | muso | writer